Seattle Genetics to Present at the Needham Cancer Therapeutics Conference

BOTHELL, Wash.--(Business Wire)--
Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Thomas C. Reynolds,
M.D., Ph.D., Chief Medical Officer, will speak at the Needham & Company Cancer
Therapeutics: Today and Tomorrow conference on Thursday, March 26, 2009 at 9:20
a.m. Eastern time. A live webcast of the presentation will be available from
Seattle Genetics` website, www.seattlegenetics.com, under the "News and Investor
Information" section.

About Seattle Genetics

Seattle Genetics is a clinical stage biotechnology company focused on the
development and commercialization of monoclonal antibody-based therapies for the
treatment of cancer and autoimmune disease. The company`s lead product
candidate, SGN-35, is in a pivotal trial under a Special Protocol Assessment
with the FDA. SGN-35 is empowered by Seattle Genetics` proprietary antibody-drug
conjugate (ADC) technology comprising highly potent synthetic drugs and stable
linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle
Genetics has three other product candidates in ongoing clinical trials:
dacetuzumab (SGN-40), lintuzumab (SGN-33) and SGN-70. Dacetuzumab is being
developed under a worldwide collaboration with Genentech. Seattle Genetics has
collaborations for its ADC technology with a number of leading biotechnology and
pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics,
Daiichi Sankyo and MedImmune, a subsidiary of AstraZeneca, as well as an ADC
co-development agreement with Agensys, a subsidiary of Astellas Pharma. More
information can be found at www.seattlegenetics.com.

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

Copyright Business Wire 2009